| Medical and Health Sciences | Lifetime | 299 | US 165 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 481 | US 166 | 99.90 |
| Hematology | Lifetime | 4 | US 4 | 99.98 |
| Molecular Biology | Lifetime | 377 | US 238 | 99.83 |
| Oncology | Lifetime | 222 | US 122 | 99.65 |
| Medical Genetics | Lifetime | 442 | US 227 | 96.03 |
| Hematology | 2021-2025 | 10 | US 6 | 99.79 |
| Molecular Biology | 2021-2025 | 371 | US 101 | 98.22 |
| Oncology | 2021-2025 | 272 | US 115 | 97.59 |
| Pharmaceutical Science | 2021-2025 | 240 | US 33 | 56.26 |
| Peptidase Inhibition and Analysis | Lifetime | 2 | US 2 | 99.98 |
| Multiple Myeloma Research and Treatments | Lifetime | 2 | US 2 | 99.98 |
| Protein Degradation and Inhibitors | Lifetime | 2 | US 2 | 99.96 |
| Ubiquitin and proteasome pathways | Lifetime | 5 | US 5 | 99.94 |
| Cancer Treatment and Pharmacology | Lifetime | 10 | US 5 | 99.93 |
| Histone Deacetylase Inhibitors Research | Lifetime | 14 | US 12 | 99.77 |
| Cancer therapeutics and mechanisms | Lifetime | 29 | US 19 | 99.70 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 132 | US 74 | 99.57 |
| Hematopoietic Stem Cell Transplantation | Lifetime | 100 | US 63 | 99.43 |
| Cancer Mechanisms and Therapy | Lifetime | 59 | US 33 | 99.12 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 125 | US 73 | 98.80 |
| Acute Myeloid Leukemia Research | Lifetime | 370 | US 174 | 98.92 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 166 | US 87 | 98.60 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 211 | US 101 | 97.27 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 539 | US 252 | 97.62 |
| Blood disorders and treatments | Lifetime | 315 | US 127 | 96.35 |
| Quinazolinone synthesis and applications | Lifetime | 646 | US 110 | 91.35 |
| Neutropenia and Cancer Infections | Lifetime | 962 | US 403 | 92.91 |
| Natural Compounds in Disease Treatment | Lifetime | 344 | US 34 | 79.43 |
| Biological Research and Disease Studies | Lifetime | 73 | US 20 | 75.89 |
| Beetle Biology and Toxicology Studies | Lifetime | 717 | US 159 | 50.11 |
| Peptidase Inhibition and Analysis | 2021-2025 | 9 | US 3 | 99.60 |
| Protein Degradation and Inhibitors | 2021-2025 | 9 | US 3 | 99.70 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 13 | US 4 | 99.81 |
| Cancer Treatment and Pharmacology | 2021-2025 | 80 | US 28 | 98.43 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 416 | US 187 | 95.80 |
| Ubiquitin and proteasome pathways | 2021-2025 | 230 | US 56 | 91.94 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 219 | US 85 | 90.22 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 459 | US 206 | 90.07 |
| Cancer Mechanisms and Therapy | 2021-2025 | 409 | US 62 | 82.91 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 651 | US 213 | 81.26 |
| Cancer therapeutics and mechanisms | 2021-2025 | 808 | US 171 | 74.74 |
| Calcium signaling and nucleotide metabolism | 2021-2025 | 299 | US 78 | 63.13 |
| Natural Product Synthesis and Anticancer Bioactivity | 2021-2025 | 273 | US 14 | 23.26 |
